ORN-101 / Orna Therap, Shanghai Simnova Bio - LARVOL DELTA

In Vivo panCARTM Therapy Using Circular RNA for the Treatment of B cell Malignancies in Oncology and Autoimmune Disease (ASGCT 2024) - "ORN-101, our first clinical candidate, is an αCD19 panCAR for the treatment of leukemia and lymphoma...LNPs deliver oRNA payloads to immune effector subsets, including T cells, NK cells and macrophages in vivo, potentially increasing efficacy and broadening application beyond hematologic malignancies. oRNA-enabled panCAR therapies promise a transient, re-dosable and scalable immune cell therapy, without requiring immunodepletion."

Circular RNA • IO biomarker • Preclinical • Colorectal Cancer • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Oncology • CD34

Orna Therapeutics Unveils Progress of Circular RNA Platform and Improvements in Lead Program ORN-101 at PEGS and ASGCT (PRNewswire) - "Orna Therapeutics...presented data on the progress of lead program ORN-101, a development-stage in situ CAR program, at the Protein Engineering Summit (PEGS) and at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Los Angeles....ORN-101, an optimized development-stage in situ CAR program, shows tumor eradication in a mouse model at doses far lower than previously reported results."

Preclinical • Oncology

"#OrnaTherapeutics to Present Progress of Lead Program #ORN101 at #PEGS23 and #ASGCT23 https://t.co/hgQMjZx4AT" (@1stOncology)

Orna Therapeutics to Present Progress of Lead Program ORN-101 at PEGS and ASGCT (PRNewswire) - "Orna Therapeutics...announced two presentations at the Protein Engineering Summit (PEGS) taking place May 15-19 in Boston as well as a poster presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Los Angeles May 16-20. Orna is presenting preclinical results for ORN-101, an in situ CAR program in development, as well as further details about its platform."

Preclinical • Oncology

Simnova and Orna Therapeutics Collaborate to Advance Orna's Next Generation Circular RNA Technology in China (PRNewswire) - "Shanghai Xianbo Biotech Co., Ltd., also known as Simnova outside of China...and Orna Therapeutics...announced a collaboration agreement to discover, develop, and commercialize multiple potential therapeutics in the area of oncology....Under the terms of the agreement, Simnova will gain access in greater China to certain programs built on Orna's breakthrough isCAR technology, including Orna's lead anti-CD19 in situ CAR (isCAR) program, ORN-101. In addition, Orna will gain access to investigator-initiated clinical trials in China to accelerate the validation of select programs in patients. Orna will receive an upfront payment from Simnova and be eligible for development, regulatory, and sales milestones as well as royalties on any approved products derived from the collaboration."

Licensing / partnership • Oncology